Related Experiment Video
Updated: Jun 10, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
LncRNA MACC1-AS1 facilitates the cell growth of small cell lung cancer by sequestering miR-579-3p and mediating
Jiang Hong1, Rentong Gu2, Wen Cheng1
1Department of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Abstract:
As reported, long non-coding RNAs (lncRNAs) have been confirmed to be of great importance in regulating the progression of diseases, especially of cancers. LncRNA MACC1 antisense RNA 1 (MACC1-AS1) has been studied in some cancers, whereas its biological role and underlying mechanism is still unclear in small cell lung cancer (SCLC). In the current research, we found high level of MACC1-AS1 in SCLC cells. Subsequently, it was discovered that MACC1-AS1 knockdown considerably restrained the proliferative and migratory ability of SCLC cells by inducing the apoptosis. Importantly, the knockdown of MACC1-AS1 inhibited protein levels of genes of NOTCH pathway, and NOTCH pathway activator (Jagged1) countervailed the inhibition of MACC1-AS1 depletion on SCLC cell growth. Further, the deficiency of NOTCH1 hampered SCLC cell growth. More importantly, miR-579-3p was identified as a downstream gene of MACC1-AS1 and thereby targeted to NOTCH1. In addition, miR-579-3p repression recovered the suppressive role of MACC1-AS1 knockdown in NOTCH1 expression. Rescue assays indicated that repressed SCLC cell growth caused by MACC1-AS1 knockdown could be reserved by miR-579-3p repression or NOTCH1 overexpression. In brief, lncRNA MACC1-AS1 boosted SCLC cell growth via sequestering miR-579-3p and mediating NOTCH1-pathway.
Insights
Long non-coding RNA MACC1-AS1 promotes small cell lung cancer (SCLC) growth by interacting with miR-579-3p and activating the NOTCH1 pathway. Inhibiting MACC1-AS1 suppressed cancer progression and induced apoptosis in SCLC cells.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Long non-coding RNAs (lncRNAs) play critical roles in disease progression, particularly in cancers.
- The specific function and mechanism of lncRNA MACC1 antisense RNA 1 (MACC1-AS1) in small cell lung cancer (SCLC) remain largely unelucidated.
Purpose of the Study:
- To investigate the biological role and underlying molecular mechanism of MACC1-AS1 in the progression of SCLC.
- To determine the relationship between MACC1-AS1, miR-579-3p, and the NOTCH1 pathway in SCLC.
Main Methods:
- Quantitative real-time PCR to measure MACC1-AS1 levels in SCLC cells.
- Cell proliferation, migration, and apoptosis assays following MACC1-AS1 knockdown.
- Western blotting to assess NOTCH pathway gene expression.
- MiRNA target prediction and validation assays.
- Rescue experiments involving miR-579-3p inhibition and NOTCH1 overexpression.
Main Results:
- MACC1-AS1 expression was significantly upregulated in SCLC cells.
- MACC1-AS1 knockdown inhibited SCLC cell proliferation and migration while inducing apoptosis.
- MACC1-AS1 knockdown suppressed NOTCH pathway activation, an effect reversed by Jagged1.
- NOTCH1 deficiency impaired SCLC cell growth.
- MACC1-AS1 was found to sequester miR-579-3p, which targets NOTCH1.
- miR-579-3p inhibition or NOTCH1 overexpression rescued the suppressive effects of MACC1-AS1 knockdown on SCLC cell growth.
Conclusions:
- lncRNA MACC1-AS1 promotes SCLC cell growth and progression.
- MACC1-AS1 exerts its oncogenic function by sponging miR-579-3p, leading to NOTCH1 pathway activation.
- Targeting MACC1-AS1 represents a potential therapeutic strategy for SCLC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Experimental RNAi
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

